SCHEMBL6320619

SCHEMBL6320619

NC1CCN(/C2=C/CCCCCC2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.36
HTR3E A5X5Y0 1/20 0.33
MEN1 O00255 1/20 0.33
HTR3B O95264 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33
HTR3A P46098 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
HRH4 Q9H3N8 1/20 0.32
AKT2 P31751 3/20 0.30
SSTR2 P30874 1/20 0.30
KIT P10721 1/20 0.30
GSK3B P49841 1/20 0.30
ROCK2 O75116 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320623 1.00 KDM1A (0.36) KDM1AHTR3EMEN1HTR3BCYP1A2
SCHEMBL11110396 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3
SCHEMBL14818806 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3
SCHEMBL8992014 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3
SCHEMBL23486255 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3
SCHEMBL23661069 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3
SCHEMBL6699994 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3
SCHEMBL8420655 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3
SCHEMBL22806637 0.80 ALDH1A1 (0.35) KDM1A
SCHEMBL497507 0.80 ALDH1A1 (0.35) KDM1AMEN1ALOX15KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113414-A1 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens CELLTECH R&D LIMITED (GB) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113414-A1 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens CXCR3, ACKR3, CCR1 KDM1A 2572/4885HTR3E 1727/4885MEN1 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.